Developing neoantigen-targeted T cell-based treatments for solid tumors

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Adoptive transfer of tumor-targeting lymphocytes shows promise in hematological cancers but has limited efficacy in solid epithelial tumors.
• Neoantigens, derived from somatic mutations unique to tumor cells, offer a potential strategy for targeted cancer destruction with minimal damage to healthy tissues.

Purpose of the Study:

• To review the promise, progress, and challenges of neoantigen-targeted T cell-based immunotherapies for cancer.
• To highlight the complexities of targeting neoantigens, including tumor heterogeneity and the biology of neoantigen recognition.

Main Methods:

• Review of current literature on neoantigen-targeted T cell therapies.
• Analysis of challenges in antigen processing, presentation, and T cell recognition in solid tumors.

Main Results:

• Neoantigen targeting holds potential for specific cancer cell destruction.
• Significant hurdles exist, including tumor antigen heterogeneity and variability in antigen processing and presentation.
• Not all tumor-expressed neoepitopes elicit a functional immune response.

Conclusions:

• Improving neoantigen-targeted T cell therapies requires addressing challenges in tumor antigen recognition and T cell function.
• Further research is needed to understand and overcome biological barriers for effective solid tumor immunotherapy.